Results 261 to 270 of about 6,230,792 (401)

Diabetic cholecystopathy [PDF]

open access: yesDiabetologia, 1968
M, Grodzki   +2 more
openaire   +3 more sources

Primary Human Tissue Models for Metabolic Dysfunction‐Associated Liver Disease ‐ toward Streamlining Drug Discovery with Patient‐Derived Assays

open access: yesAdvanced Biology, EarlyView.
The review provides a critical up‐to‐date overview of the current landscape of human in vitro models for fatty liver disease, including spheroids, organoids, organ‐on‐a‐chip systems, bioprinted liver constructs and precision‐cut liver slices. Their utility for faithfully modeling different stages of MASLD and MASH are evaluated and their compatibility ...
Sonia Youhanna   +6 more
wiley   +1 more source

K svedeniyu avtorov

open access: yesСахарный диабет, 2012
Editorial team Diabetes Mellitus
doaj   +1 more source

Introduction and Methodology: Standards of Care in Diabetes-2026. [PDF]

open access: yesDiabetes Care
American Diabetes Association Professional Practice Committee for Diabetes* .
europepmc   +1 more source

Imaging of Lipid Droplets in Living Cells and Mice with Metabolic Dysfunction‐Associated Steatotic Liver Disease via a Galactose‐Modified Supramolecular Near‐Infrared Fluorescent Glycoprobe

open access: yesAdvanced Functional Materials, EarlyView.
A galactose‐modified supramolecular near‐infrared (NIR) glycoprobe, TCF‐FBN@Gal‐BSA, enables targeted delivery to the liver through the asialoglycoprotein receptor (ASGPR) and facilitates liver‐targeting fluorescence visualization of lipid droplets (LDs) in metabolic dysfunction‐associated steatotic liver disease (MASLD) mice.
Han‐Min Wang   +12 more
wiley   +1 more source

Clinical and microbial oral health status in children and adolescents with type 1 diabetes mellitus

open access: green, 2019
Anastasia Babatzia   +6 more
openalex   +2 more sources

Russian Association of Endocrinologists reports commencement of Trajenta clinical use

open access: yesСахарный диабет, 2012
Editorial team Diabetes Mellitus
doaj   +1 more source

Home - About - Disclaimer - Privacy